Eloralintide is a chemically modified peptide clinically studied as an amylin receptor agonist. It also appears in the scientific literature under the development code LY3841136.
Available studies include receptor experiments, animal studies, and randomized clinical trials involving humans. The most extensive published data relate to a 48-week phase 2 study with weight control [1,2].
This means that eloralintide has already passed the stage of purely laboratory evaluation and is being analyzed in an advanced clinical trial program.
However, this does not mean automatic approval for commercialization or confirmation of all proposed uses.
It is also important to distinguish between the molecule itself, as defined by the formulation used in the studies, and experimental combinations with other drugs.
For example, the results of eloralintide studies in monotherapy are not the same as those regarding the combination of eloralintide with tirzepatide.
Similarly, a product labeled „eloralintide peptide” does not have to correspond to the material used in controlled clinical trials.
The article presents the molecular identity of eloralintide, its classification, structure, mechanisms of action, research results, and limitations of the available evidence.
What is eloralintide? Names, synonyms and identity of the substance
Eloralintide is a defined, experimental peptide substance developed by Eli Lilly.
The following names can be found in publications and databases of substances:
- eloralintyd;
- eloralintide;
- LY3841136;
- LY-3841136;
- AMY-1176;
- AMY1176.
The American system of substance identification assigns this molecule the UNII identifier 73G3354J8W [3].
These designations help to combine scientific publications, clinical trial documents, and descriptions of the chemical structure.
However, they do not represent several independent medicinal substances.
Do LY3841136 and eloralintyd mean the same substance?
Yes.
LY3841136 is the development code for eloralintide.
Using different names at different stages of the drug development process is a common practice in pharmaceutical research.
Recognizing synonyms helps to find previous publications.
It also avoids the mistaken treatment of the same study as several independent sources of evidence.
Does the entry in the FDA database mean approval of eloralintide?
No.
The UNII identifier is used to identify and organize information about substances.
The US FDA explicitly states that assigning an UNII number does not constitute a regulatory review or approval of a medicinal product [3].
The marketing of a drug is a separate process.
The regulatory status should be determined based on the current decisions of the competent authority, and not solely on the identification entry.
Is EloraTZP another name for eloralintide?
No.
EloraTZP is the development name for an experimental combination of eloralintide with tirzepatide.
It does not mean eloralintide itself.
In September 2026, Eli Lilly presented information regarding studies of such a combination [4].
Because it involves two substances with different mechanisms of action, its results cannot be automatically attributed solely to eloralintide.
Why do similar names for peptides not mean similar effects?
The names of substances may have similar endings, although their structure and pharmacological targets are different.
Eloralintide, larazotide, semaglutide and other peptide compounds should not be treated as substances with interchangeable mechanisms.
For proper identification, an accurate name, development code, a description of the structure, and appropriate clinical testing are required.
How is eloralintyd classified?
Eloralintide is a synthetic, chemically modified analog of the polypeptide amylin.
It is not natural amylin isolated from the body, an undefined mixture of peptides, or a biological extract.
Its primary studied pharmacological activity is the stimulation of the amylin receptors [1].
What is amylin?
Amylin is a hormone involved in the physiological regulation of metabolic processes.
The natural hormone serves as a reference point for the development of synthetic analogues.
However, this does not mean that the modified analog will have identical properties as the endogenous substance.
Modifications can affect stability, exposure time, receptor activity, and tolerance.
Each of these properties requires a separate assessment.
What does the term „aminin receptor agonist” mean?
An agonist is a substance that activates a specific receptor and triggers a signaling response in the examined system.
In the case of eloralintide, laboratory studies indicate activity against the amylin receptors, with particular emphasis on the human AMY1 receptor [1].
This does not mean that activity in all receptor subtypes is identical.
The researchers also compared the effects on the calcitonin receptor.
Is eloralintyd a GLP-1 drug?
No.
Eloralintide is studied primarily as an agonist of the amylin receptors.
It should not be classified as an GLP-1 agonist just because the studies are about weight control.
The amylin pathway differs from the GLP-1 and GIP receptor systems to which tirzepatide acts.
The combination of these substances forms a multi-pronged strategy.
However, it does not change the pharmacological classification of eloralintide itself.
Molecular structure of eloralintide – what has been established?
Eloralintyd has a defined chemical structure that includes a 37-residue peptide chain terminated by an amide C-terminal group [1].
However, it is not an ordinary, unmodified amino acid chain.
Its construction includes several characteristic modifications.
Methylthioacetal compound
In the structure of eloralintide, the remaining cystine located at positions 2 and 7 are linked by a methylene-thioacetal bond.
This is an important element of molecular identity.
It should not be substituted with a general description of a typical disarticulated bridge without appropriate structural confirmation.
The type of bond between the amino acid residues can influence the behavior of the entire molecule.
Modification of lysine at position 26
The side chain of lysine at position 26 contains a modification comprising two gamma-glutamyl units and a twenty-carbon dikarboxylic acid (C20) [1].
This modification is part of the designed structure of eloralintide.
It is not an additional component that can be omitted when describing the identity of the substance.
Non-standard amino acid residues
The official substance description also indicates the presence of such elements as:
- ornithine;
- alpha-methylphenylalanine;
- N-methylasparagina [3].
This means that the simplified sequence written in standard single-letter amino acid code would not represent the full structure of eloralintide.
Why is the exact structure so important?
In the case of modified peptides, not only the number and sequence of the amino acid residues are important.
Stereochemistry, the type of bonds, side modifications, and terminal groups are also important.
These elements can influence receptor activity, stability, and exposure.
Therefore, the name itself placed on the vial does not confirm that it contains a substance with a structure corresponding to the material clinically studied.
Does the purity of the sample confirm its equivalence with the clinically tested drug?
No.
Chemical identity, purity, concentration, degradation products, inertness, and formulation properties are separate issues.
Even a correct confirmation of the molecular structure does not prove that the finished product has identical pharmaceutical quality or safety profile.
The results of clinical studies relate to specific formulations used under controlled conditions.
They cannot be automatically transferred to products with a different composition, source or method of production.
Eloralintide in scientific studies – laboratory, animal and clinical evidence
The eloralintide research program includes several levels of evidence.
Each of them answers a different question.
Receptor studies allow the determination of pharmacological activity.
Animal experiments allow the observation of the response of the entire organism.
Early studies in humans provide information on pharmacokinetics and tolerability.
Randomized phase 2 studies, on the other hand, allow the evaluation of specific clinical outcomes in defined populations.
These categories should not be presented as a single, indistinguishable proof of effectiveness.
Laboratory and animal studies
During the development of eloralintide, receptor signaling in modified cell systems was analyzed.
Experiments were also conducted on rats and primates other than humans [1].
What results were obtained in rats?
In experiments on obese rats, a reduction in food intake and body weight was observed after the intervention.
These results provided the rationale for further development of the substance.
However, they did not in themselves confirm clinical efficacy in humans.
Interspecies differences, receptor expression, and exposure conditions limit the possibility of directly transferring results.
Why was eloralintyd compared to kagrilintyd?
In animal studies, a taste aversion conditioning test was used.
It allows to assess certain behavioral responses under experimental conditions.
Researchers used it to compare the responses to eloralintide and kagrilintide [1].
However, this was not a direct clinical study of both substances in humans.
The behavioral test results in rats do not allow to determine the difference in the frequency of nausea or the overall clinical safety of these drugs.
Early studies of eloralintide in humans
Single exposure study
A publication describing a randomized study involving 48 healthy volunteers on eloralintide was published [1].
The study involved a single exposure to the substance.
This type of project is useful for preliminary assessment of pharmacokinetics, tolerance, and selected physiological responses.
However, it does not allow one to independently assess the effectiveness of long-term treatment for obesity.
12-week phase 1 study
In another phase 1 study, repeated exposure to eloralintide was evaluated in 100 adults with overweight or obesity [5].
The study period lasted 12 weeks.
In active groups, a reduction in body weight was observed ranging from 2.6% to 11.3% kg.
The study also included an evaluation of pharmacokinetics and adverse events.
What adverse reactions have been reported?
Among the events observed during the study were:
- gastrointestinal disorders;
- headache;
- fatigue;
- decreased appetite.
Most of the reported events were of mild severity [5].
However, it is necessary to distinguish between an event occurring during treatment and an event whose causal link with the substance has been confirmed.
Small early-phase studies also do not allow for reliably detecting all rare or delayed adverse reactions.
Phase 2 study – results after 48 weeks
The most extensive published clinical data relate to a randomized Phase 2 study involving 263 adults without type 2 diabetes [2].
The study was conducted using a double-blind trial with a placebo group.
The observation period was 48 weeks.
How did the body mass change?
Depending on the studied regimen, the estimated average changes in body weight were:
- eloralintyd: approximately −9% to −20%;
- placebo: −0.4%.
These results were presented as part of a specific effectiveness analysis.
They do not mean that every person receiving eloralintide has achieved the same weight reduction.
The highest value should not be interpreted as a guaranteed result either.
What does the efficacy estimand analysis mean?
The term efficacy estimand refers to the method of defining the treatment effect that the researchers intended to estimate.
It takes into account certain assumptions regarding events occurring during the study, such as discontinuation of treatment.
Different studies may use different approaches to missing data and changes in the course of the intervention.
Therefore, the highest percentages from various publications are not always directly comparable.
What adverse events occurred in the phase 2 study?
Commonly reported side effects included nausea and fatigue.
The frequency of their occurrence differed between the analyzed schemes [2].
When evaluating the results, it is therefore necessary to take into account not only the average change in body weight, but also the tolerance to the treatment.
A study comparing several regimens does not automatically establish a single universal method of using the substance outside clinical conditions.
Phase 3 studies – ENLIGHTEN-1 and ENLIGHTEN-2
According to the registration information cited in the source material, as of October 23, 2026, two Phase 3 studies were still in the recruitment phase.
| Study | Identifier | The studied population | Planned number of participants | Status in the original review |
|---|---|---|---|---|
| ENLIGHTEN-1 | NCT07321886 | People without type 2 diabetes | 1980 | Recruitment, without published results |
| ENLIGHTEN-2 | NCT07282600 | People with type 2 diabetes | 1035 | Recruitment, without published results |
These data come from the ClinicalTrials.gov registry [6,7].
The planned number of participants does not mean that everyone has already been included in the study.
It also does not constitute evidence of additional clinical benefits.
Why are Phase 3 study results important?
Larger studies can provide more precise estimates of efficacy and safety.
They also allow for the analysis of results in broader populations.
However, the mere registration of a study or the start of recruitment does not determine its final outcome.
The registration status may change over time, therefore the information provided should be based on the date of the review.
Eloralintide and tirzepatide – research on the combination of substances
In September 2026, Eli Lilly announced research on the combination of eloralintide with tirzepatide, known as EloraTZP [4].
This is a separate line of research.
Eloralintide acts on the amylin receptors.
Tirzepatide acts on the GIP and GLP-1 receptors.
Their combination therefore has to include several regulatory systems.
Can the results of EloraTZP be attributed to eloralintide itself?
No.
The study of combinations concerns the overall effect of two substances.
To determine the additional contribution of one of them, appropriate comparison groups and an analysis of the results are needed.
The results of combination therapy should not be presented as evidence of identical efficacy of eloralintide used alone.
Does the combination with tirzepatide change the classification of eloralintide?
No.
Eloralintide remains an agonist of the amylin receptors.
The presence of tirzepatide in the study does not mean that the eloralintide molecule itself activates the GLP-1 and GIP receptors.
The classification of individual substances and the mechanism of the entire combination are separate issues.
How does eloralintide work? Mechanisms studied in experiments
The main mechanism of action of eloralintide is the activation of the amylin receptors.
The researchers evaluated its activity against various subtypes of the amylin receptor and the calcitonin receptor [1].
The results indicated a preferential activity towards the human AMY1 receptor.
Why is receptor selectivity important?
Selectivity describes differences in the activity of a substance towards specific molecular targets.
It may help to understand its pharmacological profile.
However, this does not automatically mean that the substance does not cause adverse effects.
The receptor test result and the frequency of nausea in a clinical study are different types of evidence.
How can the activity of amylin receptors be related to body weight?
Amylin-related signaling is involved in processes regulating food intake.
Decreased appetite can contribute to changes in body weight.
However, this does not mean that all the mechanisms responsible for the clinical outcome have already been explained.
Appropriate studies are needed to determine the exact contribution of individual processes.
Does a reduced appetite mean the loss of only fat tissue?
No.
Decreased appetite and body weight do not allow one to independently determine changes in the individual components of the body composition.
Body mass includes fat tissue, non-fat tissue, and water.
Therefore, claims about maintaining muscle mass or improving physical function require direct measurements.
Does extended operating time mean greater effectiveness?
Not automatically.
Longer exposure is a pharmacological property, and not a direct clinical result.
It can affect the characteristics of the substance's action.
However, the actual effectiveness and tolerance require evaluation in human studies.
Does eloralintyd have proven protective effects on the heart?
Based on the studies discussed, this conclusion cannot be confirmed.
Weight loss is not synonymous with a reduction in the incidence of heart attacks, strokes, or cardiovascular deaths.
Such results require studies with appropriately defined endpoints.
Similarly, the durability of the effects after the end of treatment cannot be assumed without appropriate observational data.
The most important limitations of the studies on eloralintide
Limited ability to generalize results
In the published phase 2 study, the majority of participants were women and people of white race.
The study did not include people with type 2 diabetes [2].
This means that the available results do not automatically predict the same response in all populations.
Phase 3 studies can help assess these differences.
However, the planned recruitment should not be considered as a published result.
Limited time of observation
The 48-week period allows for evaluating results within a specific time frame.
However, it is not sufficient to fully determine the safety of long-term treatment.
It also does not determine how long the changes in body weight persist after the exposure has ended.
No direct comparison with all other medicines
The universal superiority of eloralintide cannot be established based on a summary of the highest percentage values derived from various studies.
Populations, observation times, treatment regimens, and statistical methods may vary.
Appropriate direct studies are needed for a reliable comparison.
Greater data on safety is needed
Phase 1 and 2 studies provide information on tolerability, but do not allow all rare adverse events to be excluded.
Larger clinical trials and longer follow-up periods may help determine the frequency and nature of such events.
The absence of a problem in a small study is not proof that it may not occur later.
Funding and independent evaluation of research
Studies supported by the manufacturer can provide valuable scientific data.
At the same time, transparent reporting, the disclosure of conflicts of interest, and independent verification of results remain essential.
The assessment should be based on methodology and the quality of the evidence.
It should not be automatically rejected or accepted uncritically just because of the source of funding.
Unverified products offered online
The results of clinical studies refer to specific preparations used under controlled conditions.
They do not confirm the authenticity, stability, purity, concentration, neutrality or safety of the products offered by independent retailers.
The name itself, eloralintyd or LY3841136, does not indicate equivalence to clinical material.
Frequently asked questions about eloralintyd
1. Does eloralintyd mean a specific substance?
Yes. Eloralintyd is a chemically defined, modified peptide substance also known as LY3841136. Additional designations can be found in databases such as AMY-1176 and the UNII identifier 73G3354J8W [3]. However, this does not mean that every product labeled with this name contains the correctly identified substance. Confirmation of the identity of a specific sample requires appropriate analytical documentation.
2. What do the available studies on eloralintide confirm?
Studies confirm the erlotinib receptor activity and significant weight reduction under certain clinical study conditions [1,2]. The strongest published evidence pertains to a 48-week phase 2 study in adults without type 2 diabetes. However, it does not confirm long-term cardiovascular protection, the durability of effects after discontinuation of treatment, or universal safety. Any claim should refer to the actually measured outcome.
3. Is eloralintyd a GLP-1 drug?
No. Eloralintide is being studied as an agonist of the amylin receptors, not as an agonist of the GLP-1 receptors. Although both areas of research may relate to weight control, their pharmacological mechanisms are different. The combination of eloralintide with tirzepatide involves additional GLP-1 and GIP pathways, but does not change the classification of eloralintide itself.
4. Are eloralintyd and LY3841136 the same substance?
Yes. LY3841136 is the development code for eloralintide. Recognizing both names helps to find scientific publications and clinical trial registries. This is also important when evaluating evidence, because two documents using different names may refer to the same substance or the same study. They should not be treated automatically as independent confirmations.
5. Is eloralintyd a natural hormone?
No. Eloralintyd is a synthetic, chemically modified analogue of amylin. Natural amylin is a hormone, but eloralintyd contains additional structural elements developed through pharmaceutical research. These modifications may affect receptor activity, stability, and exposure time. Therefore, its properties require separate evaluation, rather than automatically assigning it all the characteristics of a natural hormone.
6. Does the presence of eloralintide in the FDA database mean that the drug has been approved?
No. The UNII identifier serves to identify the substance and does not constitute a permit to place a medicinal product on the market [3]. The regulatory status should be checked in the current official product registration documents. The mere presence of the name or code in the information system does not imply that the product has been approved for use in humans.
7. Is eloralintyd currently being studied in phase 3 trials?
According to the registration data cited in the original review, recruitment for ENLIGHTEN-1 and ENLIGHTEN-2 studies was conducted on October 23, 2026 [6,7]. The planned number of participants was 1980 and 1035, respectively. These were not published efficacy results. Since the study status and number of participants may change, this information should be interpreted as the status on the specified date.
8. Does the average weight reduction of 20% mean that each participant achieves such a result?
No. The value of approximately 20% represented an estimate of the average change in a specific phase 2 study design [2]. It does not mean identical responses from all participants. The result also depends on the statistical analysis method, the observation time, and the handling of missing data. The group average is not a guarantee of an individual result.
9. Does weight loss confirm the maintenance of muscle strength?
No. A change in total body mass does not allow us to determine changes in muscle strength or individual components of body composition. To confirm muscle preservation, appropriate measurements of lean body mass and physical function are needed. The result itself regarding weight loss does not prove that all the lost mass came from fat tissue.
10. Is eloralintyd safer than kagrilintyd?
No such clinical advantage has been confirmed based on the studies discussed. In experiments with rats, a conditional aversion to taste test was used as a comparator tool [1]. However, this was not a direct measurement of the frequency of adverse reactions in humans. Animal results do not allow determining which drug has a more favorable safety profile in clinical practice.
11. Does Phase 1 research allow predicting all long-term risks?
No. Early clinical studies provide information on pharmacokinetics, tolerability and selected body reactions. However, their small number and limited duration do not allow reliable detection of all rare or delayed adverse events. The absence of a specific problem in a phase 1 study does not guarantee safety during long-term treatment.
12. Are EloraTZP and eloralintyd interchangeable names?
No. EloraTZP stands for the experimental combination of eloralintide with tirzepatide [4]. Eloralintide, on the other hand, is a single substance acting on the amylin receptors. The results regarding the combination should be analyzed separately from the monotherapy studies. To determine the additional effect of each component, appropriate comparison groups are needed.
13. Does the study in people without diabetes confirm the effectiveness of eloralintud in diabetes?
No. The Phase 2 study on weight control included people without type 2 diabetes [2]. Its results do not automatically confirm glycemic efficacy or safety in patients with diabetes. Such conclusions require separate studies involving an appropriate population and direct measurements related to disease control.
14. Does a longer-acting peptide automatically provide greater effectiveness?
No. Extended exposure is a pharmacological property that can affect the course of a substance’s action. However, this does not automatically mean greater clinical efficacy or better tolerability. A beneficial balance of effects and adverse events requires direct evaluation in human studies.
15. Does the product offered online as eloralintyd have a confirmed clinical effectiveness?
No. The test results relate to specific preparations used under controlled conditions. The name on the label alone does not confirm the identity, purity, concentration, stability, sterility, or pharmaceutical quality of the product. Equivalence to the clinical material would require independent evidence regarding the specific preparation. It cannot be inferred from the existence of scientific publications.
16. Does the manufacturer’s funding of research invalidate the results?
No. Funding and interests are important elements of the evaluation of publications, but they do not automatically determine the correctness or incorrectness of the results. The significance of the research project, statistical analysis, completeness of reporting, and the possibility of independent replication of the results are all important factors. Critical interpretation should take all these factors into account.
17. What future evidence would most strongly support the conclusions regarding eloralintide?
The published results of larger clinical trials, including a detailed assessment of efficacy, safety, and handling of discontinuation cases, would be of the greatest value. Longer follow-up observations, results regarding different populations, and direct measurements of body composition and physical function would also be important. The planned number of study participants does not replace its actual results.
Applications
Eloralintide is a structurally defined, experimental analogue of amylin with confirmed receptor activity and published clinical trial results regarding weight control.
The strongest available evidence comes from a randomized, 48-week phase 2 study.
They indicate a significant decrease in body weight in a specific adult population.
However, they do not resolve all questions regarding long-term safety, the durability of the effects, efficacy in other populations, or the advantage over alternative treatment methods.
It is also necessary to distinguish between studies of elarintide used alone and experiments involving its combination with tirzepatide.
The conformity of the product name with the name of the clinically tested substance does not constitute confirmation of its authenticity or quality.
Further studies should clarify the magnitude, durability, and repeatability of the observed effects, as well as the balance of benefits and risks in broader populations.
Educational, medical and regulatory reservations
This article is for educational purposes only and serves as a critical interpretation of published scientific research. It does not constitute medical advice, diagnosis, purchase recommendations, or instructions for the use of eloralintide.
It does not contain recommendations regarding dosage, preparation of solutions, injection procedures, self-administration, or the combination of experimental substances.
Eloralintyd is presented as a substance that is still in the clinical trial phase. The results of animal experiments and studies involving humans do not confirm that the products offered online are authentic, properly manufactured, sterile, safe, or suitable for human use.
The substance identifier or development code is not an authorization to market the drug.
The reported values of weight reduction are estimates at the level of the study groups, and not a guarantee of individual results.
Gastrointestinal symptoms, fatigue, other adverse events, and unresolved issues regarding long-term safety remain important elements of the assessment of the evidence.
Individuals requiring diagnosis or treatment for obesity, diabetes, and other diseases should benefit from the assistance of appropriately qualified medical personnel and up-to-date guidelines based on scientific evidence.
References
- Briere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coskun, T., Long, A., Allen, D., O’Farrell, L., Bowen, B., Pratt, E., Tidemann-Miller, B., Tham, L. S., Ibriga, H., Alsina-Fernandez, J., Mather, K. J., Haupt, A., & Bhattachar, S. N. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism, 102, 102271. https://doi.org/10.1016/j.molmet.2025.102271
- Billings, L. K., Hsia, S., Bays, H., Tidemann-Miller, B., O’Hagan, J., Tham, L. S., Butler, A., Kazda, C., Mather, K. J., & Coskun, T. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicenter, double-blind, randomized, placebo-controlled trial. Lancet (London, England), 406(10520), 2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
- U.S. Food and Drug Administration. (n.d.). Eloralintide (UNII: 73G3354J8W) [Substance identity record]. Retrieved October 23, 2026, from https://precision.fda.gov/uniisearch/srs/unii/73G3354J8W
- Eli Lilly and Company. (2026, September). What to know about eloralintide [Developer update]. https://www.lilly.com/news/stories/what-to-know-about-eloralintide
- Bhattachar, S., Tham, L. S., Tidemann-Miller, B., Ibriga, H., Qu, H., Briere, D. A., Haupt, A., Mather, K. J., & Pratt, E. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for the treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 28(4), 2651–2660. https://doi.org/10.1111/dom.70439
- Eli Lilly and Company. (2026). A Study of Eloralintide (LY3841136) in Participants with Obesity, or Overweight Without Type 2 Diabetes (NCT07321886) [Clinical trial registration]. ClinicalTrials.gov. Retrieved October 23, 2026, from https://clinicaltrials.gov/study/NCT07321886
- Eli Lilly and Company. (2026). A Study of Eloralintide (LY3841136) in Participants with Obesity or Overweight, and Type 2 Diabetes (NCT07282600) [Clinical trial registration]. ClinicalTrials.gov. Retrieved October 23, 2026, from https://clinicaltrials.gov/study/NCT07282600